Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis

References

• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
   PubMed Web of Science ®Google Scholar
• Yu T, Zhang Q, Zheng T, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One. 2016;11:e0154499.
   PubMed Web of Science ®Google Scholar
• Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol). 2012;24:461–473.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Nakamura S, Nishimura T, et al. Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res. 2014;55:1033–1047.
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16:234.
   PubMed Web of Science ®Google Scholar
• Schneider U, Lomax A, Pemler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol. 2006;182:647–652.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69:444–453.
   PubMed Web of Science ®Google Scholar
• Vargas C, Fryer A, Mahajan C, et al. Dose–volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:744–751.
   PubMed Web of Science ®Google Scholar
• Zips D, Baumann M. Place of proton radiotherapy in future radiotherapy practice. Semin Radiat Oncol. 2013;23:149–153.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419.
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047–1060.
   PubMed Web of Science ®Google Scholar
• Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95:422–434.
   PubMed Web of Science ®Google Scholar
• Schulte RW, Slater JD, Rossi CJ, Jr, et al. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol. 2000;176:3–8.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Hoppe BS, Nichols RC, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88:596–602.
   PubMed Web of Science ®Google Scholar
• Iwata H, Ishikawa H, Takagi M, et al. Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 2018;7:677–689.
   PubMed Web of Science ®Google Scholar
• Sheets NC, Goldin GH, Meyer A, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–1620.
   PubMed Web of Science ®Google Scholar
• Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105:25–32.
   PubMedGoogle Scholar
• Fang P, Mick R, Deville C, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer. 2015;121:1118–1127.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014;120:1076–1082.
   PubMed Web of Science ®Google Scholar
• Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013;119:1729–1735.
   PubMed Web of Science ®Google Scholar
• O’Doherty ÚM, McNair HA, Norman AR, et al. Variability of bladder filling in patients receiving radical radiotherapy to the prostate. Radiother Oncol. 2006;79:335–340.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• van Andel G, Bottomley A, Fosså SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–2424.
   PubMed Web of Science ®Google Scholar
• Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceut Statist. 2011;10:150–161.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson N, Bjordal K, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Munsell MF, Choi S, et al. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;87:946–953.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129.
   PubMed Web of Science ®Google Scholar
• Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J Clin Oncol. 2018;36:1823–1830.
   PubMed Web of Science ®Google Scholar
• Zhang X, Dong L, Lee AK, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007;67:620–629.
   PubMed Web of Science ®Google Scholar
• Makishima H, Ishikawa H, Tanaka K, et al. A retrospective study of late adverse events in proton beam therapy for prostate cancer. Mol Clin Oncol. 2017;7:547–552.
   PubMed Web of Science ®Google Scholar
• Viswanathan AN, Yorke ED, Marks LB, et al. Radiation dose–volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010;76:S116–S122.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yorke ED, Jackson A, et al. The use of normal tissue complication probability (NTCP) models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–S19.
   PubMed Web of Science ®Google Scholar
• Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325–2332.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, et al. Radiation dose–volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76:S123–S129.
   PubMed Web of Science ®Google Scholar
• Scott N, Fayers P, Aaronson N, et al. EORTC QLQ-C30 reference values manual. 2nd ed. Brussels, Belgium: EORTC Quality of Life Group; 2008.
   Google Scholar
• Cuypers M, Lamers RED, Cornel EB, et al. The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset. Support Care Cancer. 2018;26:1297–1304.
   PubMed Web of Science ®Google Scholar
• Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys. 2007;69:656–661.
   PubMed Web of Science ®Google Scholar
• van Leeuwen M, Kieffer JM, Efficace F, et al. International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. Health Qual Life Outcomes. 2017;15:97.
   PubMed Web of Science ®Google Scholar
• Drummond FJ, Kinnear H, O’Leary E, et al. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (prostate cancer treatment, your experience) study. J Cancer Surviv. 2015;9:361–372.
   PubMed Web of Science ®Google Scholar
• Henderson RH, Hoppe BS, Marcus RB, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol. 2013;52:463–469.
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105.
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273.
   PubMed Web of Science ®Google Scholar